Drug Profile
Research programme: microbiome targeted therapeutics - Symberix
Alternative Names: Bacterial enzyme inhibitors - SymberixLatest Information Update: 28 Dec 2019
Price :
$50
*
At a glance
- Originator Symberix
- Class Small molecules
- Mechanism of Action Bacterial protein inhibitors; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastrointestinal disorders
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA
- 18 Oct 2018 Symberix entered into a research collaboration agreement with National Center for Advancing Translational Sciences for microbiome targeted therapeutics
- 20 Nov 2015 Preclinical trials in Gastrointestinal disorders in USA (unspecified route)